Table 3. TTR and proportion of INR 2.0–3.0 included in TTR analysis in each center.
Center | No. | Mean TTR (95% CI) | INR 2.0–3.0 (%) |
---|---|---|---|
1 | 88 | 55.9 (52.3–59.5) | 46.3 |
2 | 95 | 47.4 (43.1–51.7) | 42.9 |
3 | 63 | 51.7 (47.5–56.0) | 40.9 |
4 | 56 | 42.7 (38.0–47.4) | 36.1 |
5* | 121 | 58.4 (54.9–61.9) | 51.7 |
6 | 64 | 45.6 (40.8–50.4) | 46.1 |
7 | 31 | 45.6 (39.3–51.8) | 40.4 |
8 | 60 | 37.1 (32.2–42.0) | 37.0 |
9 | 48 | 50.0 (45.0–55.0) | 44.2 |
10 | 38 | 49.2 (41.7–56.7) | 44.9 |
11* | 107 | 57.5 (53.7–61.3) | 53.4 |
12 | 39 | 50.6 (44.0–57.2) | 47.9 |
13 | 129 | 38.6 (35.1–42.0) | 36.4 |
14 | 131 | 53.6 (49.9–57.2) | 50.1 |
15 | 59 | 37.3 (32.0–42.6) | 37.7 |
16* | 101 | 50.4 (46.0–54.8) | 43.6 |
Data are mean (95% CI) or % values.
*Centers in which warfarin therapy was managed by a formal anticoagulation clinic during the study period.
INR: international normalized ratio, TTR: time in therapeutic range.